The Supreme Court heard arguments this week in Amgen v. Sanofi, the closely-watched case involving the enablement standard for patent claims, particularly as applied to functionally-defined genus claims. The question raised...more
3/29/2023
/ Amgen ,
Biotechnology ,
Enablement Inquiries ,
Healthcare ,
Inventions ,
Judicial Proceedings ,
Life Sciences ,
Oral Argument ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Sanofi ,
SCOTUS